Minerva Neurosciences, Inc. (NERV)

Pharmaceutical Preparations · market cap $172M · as of 2026-07-22

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-11-04 (est.)

Earnings

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

Minerva Neurosciences (NERV) is a clinical-stage pharmaceutical company with a market cap of ~$204M and ~$32.7M in cash (runway ~18 months). Its lead asset is roluperidone 32 mg in Phase 3 for negative symptoms of schizophrenia, with a secondary Phase 2 asset (MIN-117) in major depressive disorder.

The catalyst path

2026-11-04 (est.)Earningsimp 5/10

Pipeline

Asset	Phase	Indication
MIN-117 5.0 mg	Phase 2	Major Depressive Disorder
Roluperidone 32 mg	Phase 3	Negative Symptoms of Schizophrenia

Price & technical context

3-month

-34.3%

6-month

-38.8%

12-month

+53.8%

52-wk range

$2.10–$8.07

vs 50-day MA

-22.3%

vs 200-day MA

-36.1%

Realized vol

129.0%

Max drawdown

-60.0%

Daily closes through 2026-10-02. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

Sources & data

SEC filings — EDGAR filings for NERV (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 2 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.